8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder

European Neuropsychopharmacology

Volumn 18, Issue 5, 2008, Pages 364-372

  Maina, Giuseppe ^a   Pessina, Enrico ^a   Albert, Umberto ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Obsessive compulsive disorder; Olanzapine; Risperidone; Treatment resistant

Indexed keywords

OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIBIDO; LIBIDO DISORDER; MALE; MENTAL STRESS; MICTURITION DISORDER; MUSCLE RIGIDITY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; VOMITING; WEIGHT GAIN;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PROSPECTIVE STUDIES; RISPERIDONE; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 40849117961     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.01.001     Document Type: Article

References (53)

1. Albert U., Aguglia E., Maina G., and Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J. Clin. Psychiatry 63 11 (2002) 1004-1009
2. Albert U., Bergesio C., Pessina E., Maina G., and Bogetto F. Management of treatment resistant obsessive-compulsive disorder. Panminerva Med. 44 (2002) 83-91
3. Albert U., Maina G., Forner F., and Bogetto F. DSM-IV obsessive-compulsive personality disorder: prevalence in patients with anxiety disorders and in healthy comparison subjects. Compr. Psychiatry 45 (2004) 325-332
4. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., Coric V., Bracken M.B., and Leckman J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol. Psychiatry 11 (2006) 622-632
5. Bogetto F., Bellino S., Vaschetto P., and Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 96 (2000) 91-98
6. Bystritsky A., Ackerman D.L., Rosen R.M., Vapnik T., Gorbis E., Maidment K.M., and Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J. Clin. Psychiatry 65 (2004) 565-568
7. Carey P.D., Vythilingum B., Seedat S., Muller J.E., van Ameringen M., and Stein D.J. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind randomized, placebo-controlled study. BMC Psychiatry 5 (2005) 5
8. Crocq M.A., Leclercq P., Guillon M.S., and Bailey P.E. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur. Psychiatr. 17 (2002) 296-297
9. D'Amico G., Cedro C., Muscatello M.R., Pandolfo G., Di Rosa A.E., Zoccali R., La Torre D., D'Arrigo C., and Spina E. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuro-psychopharmacol Biol. Psychiatry 27 (2003) 619-623
10. Delgado P.L., Goodman W.K., Price L.H., Heninger G.R., and Chamey D.S. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br. J. Psychiatry 157 (1990) 762-765
11. Dell'Osso B., Altamura A.C., Mundo E., Marazziti D., and Hollander E. Diagnosis and treatment of obsessive-compulsive disorder and related disorders. Int. J. Clin. Pract. 61 1 (2007) 98-104
12. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr. Clin. North Am. 29 (2006) 553-584
13. Denys D., De Geus F., Van Megen H., and Westenberg H.G.M. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry 65 (2004) 1040-1048
14. Denys D., Fineberg N., Carey P.D., and Stein D.J. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?. Biol. Psychiatry 61 3 (2007) 412-414
15. Erzegovesi S., Guglielmo E., Siliprandi F., and Bellodi L. Low-dose augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 15 (2005) 69-74
16. Fineberg N.A., Sivakumaran T., Roberts A., and Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder : a randomized controlled treatment study. Int. Clin. Psychopharmacol. 20 (2005) 223-226
17. Fineberg N.A., Stein D.J., Premkumar P., Carey P., Sivakumaran T., Vythilingum B., Seedat S., Westenberg H., and Denys D. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int. Clin. Psychopharmacol. 21 6 (2006) 337-343
18. Fineberg N.A., Tonnoir B., Lemming O., and Stein D.J. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 17 (2007) 430-439
19. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can. J. Psychiatry 46 (2001) 356-358
20. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch. Gen. Psychiatry 46 (1989) 1006-1011
21. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch. Gen. Psychiatry 46 (1989) 1012-1016
22. Greist H.J., Chouinard G., DuBoff E., Halaris A., Kim S.W., Koran L., Liebowitz M., Lydiard R.B., Rasmussen S., and White K. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch. Gen. Psychiatry 52 (1995) 289-295
23. Guy W. ECDEU Assessment Manual for Psychopharmacology (1987), US Dept of Health and Human Services. Publication ABM, Washington, DC
24. Hollander E., Rossi N.B., Sood E., and Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 6 (2003) 397-401
25. Ipser J.C., Carey P., Dhansey P., Fakier N., Seedat S., and Stein D.J. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 18 (2006) CD005473
26. Kapur S., Remington G., Zipursky R.B., Wilson A.A., and Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 57 (1995) 103-107
27. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., and Houle S. 5HT-2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry 155 (1998) 921-928
28. Koran L.M., Ringold A.L., and Elliott M.A. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry 61 (2000) 514-517
29. Li X., May R., Tolbert L.C., Jackson W.T., Flournoy J.M., and Baxter L.R. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J. Clin. Psychiatry 66 (2005) 736-743
30. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU Side Effect Rating Scale. Acta Psychiatr. Scand. 76 suppl. 334 (1987) 1-100
31. Maina G., Albert U., Ziero S., and Bogetto F. Antipsychotic augmentation for treatment-resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?. Int. Clin. Psychopharmacol. 18 (2003) 23-28
32. Maina G., Albert U., and Bogetto F. Obsessive-compulsive disorder resistant to pharmacological treatment. In: Ling B.E. (Ed). Obsessive-Compulsive Disorder Research (2005), Nova Science Publishers, Inc., New York 171-199
33. Maina G., Albert U., Pessina E., Salvi V., and Bogetto F. Antipsychotics in obsessive-compulsive disorder. Curr. Psychiatry Rev. 1 (2005) 292-301
34. In: March J., Frances A., Carpenter D., and Kahn D. (Eds). The Expert Consensus Guideline Series. Treatment of Obsessive-Compulsive Disorder. J. Clin. Psychiatry vol. 58(suppl.4) (1997)
35. McDougle C.J., Goodman W.K., Price L.H., Delgado P.L., Krystal J.H., Carney D.S., and Heninger G.R. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry 147 (1990) 652-654
36. McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., and Price L.H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry 51 (1994) 302-308
37. McDougle C.J., Epperson C.N., Pelton G.H., Wasylink S., and Price L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry 57 (2000) 794-801
38. Montgomery S.A., McIntyre A., Osterheider M., et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur. Neuropsychopharmacol. 3 2 (1993) 143-152
39. Montgomery S.A., Kasper S., Stein D.J., Bang Hedergaard K., and Lemming O.M. Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 16 2 (2001) 75-86
40. Ninan P.T., Koran L.M., Kiev A., Davidson J., Rasmussen S.A., Zajecka J.M., Robinson D.G., Crits-Christoph P., Mandel F.S., and Austin C. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J. Clin. Psychiatry 67 (2006) 15-22
41. Nyberg S., Eriksson B., Oxenstierna G., Halldin C., and Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5HT2 receptor occupancy in schizophrenic patients. Am. J. Psychiatry 156 (1999) 869-875
42. Nyberg S., Farde L., Eriksson L., Halldin C., and Eriksson B. 5HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 110 3 (1993) 265-272
43. Pfanner C., Marazziti D., Dell'Osso L., Presta S., Gemignani A., Milanfranchi A., and Cassano G.B. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int. Clin. Psychopharmacol. 15 (2000) 297-301
44. Ravizza L., Barzega G., Bellino S., Bogetto F., and Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull. 32 (1996) 677-682
45. Salmeron J.M., Alcantara A.G., and Barcia D. Combination of risperidone and serotonergic antidepressant in refractory obsessive-compulsive disorder. Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines 26 (1998) 399-402
46. Saxena S., Wang D., Bystritsky A., and Baxter Jr. L.R. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry 57 (1996) 303-306
47. Shapira N.A., Ward H.E., Mandoki M., Murphy T.K., Yang M.C.K., Blier P., and Goodman W.K. A double blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol. Psichiatry 550 (2004) 553-555
48. Skapinakis P., Papatheodorou T., and Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trias. Eur. Neuropsychopharmacol. 17 (2007) 79-93
49. Spitzer R.L., Williams J.B.W., and Gibbon M. Structured Clinical Interview for DSM-IV (SCID) (1995), Biometric Research, NewYork State Psychiatric Institute, New York, NY
50. Stein D.J., Bouwer C., Hawkridge S., and Emsley R.A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J. Clin. Psychiatry 58 (1997) 119-122
51. Tollefson G., Rampey A., Potvin J., Jenike M.A., Rush A.J., Dominguez R.A., Koran L.M., Shear M.K., Goodman W., and Genduso L.A. A multi-center investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry 51 (1994) 559-567
52. Weiss E.L., Potenza M.N., McDougle C.J., and Epperson C.N. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J. Clin. Psychiatry 60 (1999) 524-527
53. Wheadon D.E., Bushnell W.D., and Steiner M. A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder. Abstracts of Panels and Posters presented at the Annual Meeting of the American College of Neuropsychopharmacology (1993), Vanderbilt University, Nashville, TN